|
Robert Peterson, MD, PhD, MPH
Dr. Peterson is a pediatrician, clinical pharmacologist, and medical
toxicologist, who is a Clinical Professor in the Department of Pediatrics, University of British Columbia. He is Chair of the
Regulations Advisory Board of the Centre for Medicines Research,
International. In this capacity, he participates actively in international
drug development, and regulation review and discussion. He was Director
General of the Therapeutic Products Directorate at Health Canada for
five years, and led many innovations in drug regulatory policy during that
time. Dr Peterson has experience in clinical trials, been director of a research
institute, and has participated in numerous international workshops on drug
development. He completed a Masters of Public Health in the area of Health
Policy and Healthcare Management, and has a good appreciation of the
evaluation and use of human prescription drugs. Dr. Peterson has been a
member of CEDAC since 2005.
Conflict of Interest Disclosure
Anne Holbrook, MD, PharmD, MSc, FRCPC
Dr. Holbrook is a clinical pharmacologist and internal medicine specialist
with expertise in pharmacoepidemiology, at the Centre for Evaluation of
Medicines, St. Joseph's Hospital and Hamilton Health Sciences Corporation in
Hamilton. She is a Professor and Director, Division of Clinical Pharmacology
& Therapeutics in the Department of Medicine at McMaster University.
Dr. Holbrook has broad experience and expertise in evidence-based
therapeutics research, education, and practice. She has chaired and held
appointments with numerous federal, provincial, and regional committees,
including serving as Chair of the federal Expert Advisory Committee on
Pharmacovigilance, and as a member of the Ontario Program for Optimal
Therapeutics. Dr. Holbrook has been a member of Ontario's Drug Quality and Therapeutics
Committee (DQTC) since 1997, and has participated on and chaired
subcommittees on a variety of drug topics.
Conflict of Interest Disclosure
Members
G. Michael Allan, MD, CCFP
Dr. Allan is an Associate Professor and Director of Evidence-Based Medicine
in the Department of Family Medicine at the University of Alberta.
He coordinates and teaches the evidence-based medicine curriculum in the
family medicine residency program and the community health course. In August
2008, he assumed the new role of Medical Director of the Toward Optimized
Practice Program. This role will focus on expanding the depth and spread of
evidence-based practice and quality of primary care in Alberta. In addition, Dr. Allan teaches at
conferences, does research in Health Care Economics and Physician Education
and practices family medicine in a multi-disciplinary team setting. He also
co-presents a weekly evidence-based educational podcast with the Therapeutics
Initiative.
Conflict of Interest Disclosure
Ken Bassett, MD, PhD
Dr Ken Bassett is a professor in the Departments of Family Practice,
Pharmacology and Therapeutics, Health Care and Epidemiology, and
Ophthalmology as well as a senior medical consultant at the Centre for Health
Services and Policy Research at the University of British Columbia (UBC) Dr
Bassett's research interests are in the systematic review of drug therapy and
drug funding policy. He is highly experienced and skilled in the critical
appraisal of drug therapies, and has had considerable experience with
practical issues around public plan formularies. Dr. Bassett has chaired and
held appointments with numerous federal and provincial or local committees,
including serving as Chair of the Drug Assessment Working Group of the UBC
Therapeutics Initiative.
Conflict of Interest Disclosure
Bruce Carleton, BPharm, PharmD
Dr. Carleton is a Professor of Paediatrics and Pharmaceutical Sciences at the
University of British Columbia (UBC). He is also the Director of the
Pharmaceutical Outcomes Program, Children's and Women's Health Centre of BC,
and Distinguished Scholar at the Child and Family Research Institute in Vancouver. Dr.
Carleton's relevant experience in the area of drug policy implementation and
evaluation includes work as a reviewer of clinical and pharmacoeconomic
studies of drugs. He is experienced and skilled in the critical appraisal of
drug therapies, and has had considerable experience with practical issues
around public plan formularies. He has served on both provincial and federal
committees focused on drug effectiveness, drug safety and drug policy
development.
Conflict of Interest Disclosure
Douglas (Doug) Coyle, MA, MSc, PhD
Dr. Coyle is a Professor
and the Director of Graduate Studies in the Department of Epidemiology and
Community Medicine at the University
of Ottawa. He is also a
Senior Scientist at the Ottawa Hospital Research Institute and a former
Research Fellow at the Centre for Health Economics, University of York, England.
He has been a member of the Ontario Committee to Evaluate Drugs since 2006 and
the Ontario Drugs for Rare Diseases Working Group since 2008.
Conflict of Interest Disclosure
John Deven
Mr. Deven is a retired high school principal from Ontario. His undergraduate and graduate
degrees are in biochemistry, microbiology and pathology. He has been involved
in many committees as chair or vice-chair including the Hamilton-Wentworth
Community Policing Committee, the Teachers’ Credit Union Board of Directors,
the Hamilton-Wentworth Lung Association, many education-related committees
and leadership development programs. Mr. Deven was awarded the Mayor’s Award
for Multiculturalism and Anti-Racism from the City of Hamilton, the Ontario Teachers’ Excellence
in Education Award and the Royal Canadian Legion’s Community Involvement
Award.
Conflict of Interest Disclosure
Alan Forster , MD, FRCPC, MSc
Dr. Forster is a general internist and Co-Director of the Ottawa Hospital
Center for Patient
Safety. He is an Associate Professor of Medicine at the University of Ottawa
and Scientist in the Clinical Epidemiology Program at the Ottawa Health
Research Institute, where his research focuses on patient safety and quality
improvement. He has been the recipient of several prestigious awards
recognizing his work within the field of health services research. He has
performed seminal work evaluating the incidence of adverse events following
discharge from hospital. This work has lead to the development of strategies
to improve care during the transition home from hospital. He is also leading
in the development of a hospital data warehouse, which will serve as a
supporting infrastructure for a research program in patient safety and
quality of care. In addition to his significant contributions to a quality
and safety program at the Ottawa
Hospital, he provides
ongoing scientific advice regarding quality of care to provincial and
national organizations, such as the Ontario Health Quality Council and the
Canadian Institute for Health Information.
Conflict of Interest Disclosure
Laurie Mallery, MD, FRCPC
Dr. Mallery is the Head of the Division of Geriatric Medicine at Dalhousie
University and the Director of the Centre for Health Care of the Elderly at
the Queen Elizabeth II Health Sciences Centre in Halifax. She is a
Geriatrician and internist who is committed to evidence-based decision-making
and has experience with the drug evaluation process. She was a member of the
Nova Scotia Formulary Management Committee since 1993 and served as Chair
since 2000. She has chaired the Atlantic Common Drug Review Expert Advisory
Committee since it was established in 2002.
Conflict of Interest Disclosure
Brad Neubauer
Mr. Neubauer, a rancher and businessman in Irvine, Alberta,
holds a Bachelor of Arts degree in Political Science and Philosophy. He has
been actively involved as a member of the public in health care and has
served as a member of local and provincial bioethics and research ethics
committees. Mr. Neubauer has also volunteered his time and efforts in support
of the local theatre community in Medicine
Hat.
Conflict of Interest Disclosure
Lindsay Nicolle, MD, FRCPC
Dr. Nicolle is Professor of Internal Medicine and Medical Microbiology at
the University
of Manitoba and
Consultant in Adult Infectious Diseases at the Health Sciences Centre and
Winnipeg Regional Health Authority. She was Chair of the Department of
Internal Medicine at the University
of Manitoba from 1996 –
2001 where she has also previously served as a member and Chair of the
Antimicrobial Review and Pharmacy and Therapeutics Committees. During a
sabbatical at the World Health Organization in 2001, Dr. Nicolle participated
in the development of the Global Strategy for Antimicrobial Resistance.
Conflict of Interest Disclosure
Yvonne Shevchuk , B.S.P., Pharm D
Dr. Shevchuk is a Professor in the College of Pharmacy and Nutrition at the
University of Saskatchewan where her areas of teaching focus include
infectious diseases and research methods/evidence-based pharmacotherapy and
drug information. Dr. Shevchuk is a long-time member of the Infectious
Diseases Service at the Royal
University Hospital
and is involved in direct patient care. She has extensive committee
experience, serving on both the Saskatchewan Formulary Committee and the Drug
Quality Assessment Committee since 1991. She has just recently (2008) been
appointed Acting Chair of the Drug Quality Assessment Committee. In addition,
Dr. Shevchuk has served on the Board of the Saskatchewan Health Quality
Council, and currently serves on the Saskatoon Health Region Quality Council,
the Advisory Board of RxFiles and is Director of the Saskatchewan Drug
Information Service.
Conflict of Interest Disclosure
Kelly Zarnke, MD, MSc, FRCPC
Dr. Zarnke, an internist and clinical pharmacologist, holds appointments as
Associate Professor in the Department of Medicine at the University of Calgary
and as Medical Director of Therapeutics for the Calgary Health Region. He
also has formal training in Clinical Epidemiology and Pharmacoeconomics. Dr.
Zarnke was an Associate Professor at the University of Western
Ontario from 1996 – 2007 and also served as the
medical Leader of Pharmacy at the London Health Sciences Centre. He has been
a member of the Ontario Committee to Evaluate Drugs (CED) and served as the
Chair of the CED/Cancer Care Ontario Subcommittee from 2005-07.
Conflict of Interest Disclosure
|
